91 related articles for article (PubMed ID: 38466436)
1. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
Ge S; Li J; Yu Y; Chen Z; Yang Y; Zhu L; Sang S; Deng S
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770887
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
[TBL] [Abstract][Full Text] [Related]
3. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.
Gao F; Liu F; Wang J; Bi J; Zhai L; Li D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):118. PubMed ID: 38466436
[TBL] [Abstract][Full Text] [Related]
4. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
[TBL] [Abstract][Full Text] [Related]
5. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
[TBL] [Abstract][Full Text] [Related]
6. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
9.
Altunay B; Goedicke A; Winz OH; Hertel F; von Mallek D; Meszaros LK; Chand G; Biersack HJ; Stickeler E; Krauss K; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1005-1013. PubMed ID: 36482076
[TBL] [Abstract][Full Text] [Related]
10.
Suman SK; Mukherjee A; Pandey U; Chakraborty A; Rakshit S; Tawate M; Sarma HD
Cancer Biother Radiopharm; 2023 Feb; 38(1):38-50. PubMed ID: 36413344
[No Abstract] [Full Text] [Related]
11. Evaluation of
Ducharme M; Houson HA; Fernandez SR; Lapi SE
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36359554
[TBL] [Abstract][Full Text] [Related]
12. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
13. The Prediction of HER2-Targeted Treatment Response Using
Lee I; Lim I; Byun BH; Kim BI; Choi CW; Lee KC; Kang CM; Seong MK; Kim HA; Noh WC; Lim SM
J Breast Cancer; 2022 Feb; 25(1):69-73. PubMed ID: 35133094
[TBL] [Abstract][Full Text] [Related]
14. Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients.
Rathore Y; Shukla J; Laroiya I; Deep A; Lakhanpal T; Kumar R; Singh H; Bal A; Singh G; Gopal Thakur K; Mittal BR
Nucl Med Commun; 2022 Apr; 43(4):458-467. PubMed ID: 35131966
[TBL] [Abstract][Full Text] [Related]
15. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
